Literature DB >> 10960464

Standardization of hepatitis C virus RNA quantification.

J M Pawlotsky1, M Bouvier-Alias, C Hezode, F Darthuy, J Remire, D Dhumeaux.   

Abstract

It was recently recommended that hepatitis C virus (HCV) RNA quantification be used to tailor the duration of combined interferon alfa (IFN-alpha)/ribavirin therapy in patients infected by HCV genotypes 1, 4, and 5. This recommendation has been difficult to implement in the absence of standardized quantitative units for HCV RNA. The aim of this work was to define clinically relevant HCV RNA loads in standardized international units (IU), for use in routine clinical and research applications based on standardized quantitative assays. Two hepatitis C virus RNA quantitative assays were used: (1) the Superquant assay (National Genetics Institute, Los Angeles, CA), for which possibly relevant thresholds were established; and (2) the semi-automated Cobas Amplicor HCV Monitor assay version 2.0 (Cobas v2.0, Roche Molecular Systems, Pleasanton, CA) that measures HCV RNA loads in IU/mL. Quantification in the Cobas v2.0 assay was linear over the entire range of values tested, including viral loads higher than 850,000 IU/mL after 100-fold dilution. The accuracy and precision of the measures in IU/mL were satisfactory with Cobas v2.0. The results obtained with Superquant and Cobas v2.0 correlated (r =.932; P <.0001). A value of 2,000,000 copies/mL (6.3 log(10) copies/mL) with Superquant was converted to nearly 800,000 IU/mL (5.9 log(10) IU/mL). In conclusion, all HCV RNA quantitative assays should give HCV RNA loads in international units and be validated with appropriate calibrated panels; 800,000 IU/mL in any of these assays should be used as the decision threshold to tailor the IFN-alpha/ribavirin treatment duration in patients infected by HCV genotypes 1, 4, and 5.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960464     DOI: 10.1053/jhep.2000.16603

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 2.  Guidelines for stopping therapy in chronic hepatitis C.

Authors:  Mark W Russo; Michael W Fried
Journal:  Curr Gastroenterol Rep       Date:  2004-02

3.  Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients.

Authors:  V Descamps; A Op de Beeck; C Plassart; E Brochot; C François; F Helle; M Adler; N Bourgeois; D Degré; G Duverlie; S Castelain
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

4.  Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

Authors:  Maria H Sjogren; Robert Sjogren; Kent Holtzmuller; Bradley Winston; Betty Butterfield; Stanley Drake; Amber Watts; Robin Howard; Milton Smith
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 5.  Current therapy for hepatitis C.

Authors:  Mireen Friedrich-Rust; Stefan Zeuzem; Christoph Sarrazin
Journal:  Int J Colorectal Dis       Date:  2005-09-21       Impact factor: 2.571

6.  Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.

Authors:  Th Witthoeft; M Fuchs; D Ludwig
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

7.  Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.

Authors:  Marek J Nowicki; Tomasz Laskus; Georgia Nikolopoulou; Marek Radkowski; Jeffrey Wilkinson; Wenbo B Du; Jorge Rakela; Andrea Kovacs
Journal:  J Infect Dis       Date:  2005-09-29       Impact factor: 5.226

8.  Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.

Authors:  Christopher M Moore; Magdalena George; David H Van Thiel
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

9.  Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Authors:  Tatsuya Kanto; Michiyo Inoue; Tsugiko Oze; Masanori Miyazaki; Mitsuru Sakakibara; Naruyasu Kakita; Tokuhiro Matsubara; Koyo Higashitani; Hideki Hagiwara; Sadaharu Iio; Kazuhiro Katayama; Eiji Mita; Akinori Kasahara; Naoki Hiramatsu; Tetsuo Takehara; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-09-27       Impact factor: 7.527

10.  Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.

Authors:  Micaela B Reddy; Peter N Morcos; Sophie Le Pogam; Ying Ou; Karl Frank; Thierry Lave; Patrick Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.